Peer-influenced content. Sources you trust. No registration required. This is HCN.
Already approved to treat ovarian cancer, Rubraca (rucaparib) has been granted accelerated approval as the first PARP inhibitor to treat certain patients with prostate cancer, offering a completely new approach for physicians.
Hematology May 25th 2020
The New England Journal of Medicine
Longer overall survival and similar safety profile were the endpoints in this NEJM piece, comparing those who received osimertinib with those who received a comparator EGFR-TKI.
Internal Medicine March 16th 2020